DXCMHealthcare · Medical DevicesThe 28 Wall Street analysts covering DexCom, Inc. hold a median 12-month price target of $94 — +7.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 23 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores DexCom, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (99): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (69): The shares have been drifting down relative to others.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DXCM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +7.5% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Sept 2026 | TD Cowen | Reiterates | Buy | $95 |
| 18 Sept 2026 | Truist Securities | Maintains | Buy | $93 → $102 |
| 4 Aug 2026 | Argus Research | Maintains | Buy | — |
| 4 Aug 2026 | Argus Research | Maintains | Buy | $86 → $96 |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Buy | $82 → $90 |
| 31 July 2026 | Benchmark | Maintains | Buy | — |
| 31 July 2026 | Benchmark | Maintains | Buy | $77 → $82 |
| 31 July 2026 | BTIG | Maintains | Buy | $80 → $90 |
| 31 July 2026 | BTIG | Maintains | Buy | — |
| 31 July 2026 | Citigroup | Maintains | Buy | — |
| 31 July 2026 | Citigroup | Maintains | Buy | $84 → $88 |
| 31 July 2026 | JP Morgan | Maintains | Neutral | — |
| 31 July 2026 | JP Morgan | Maintains | Neutral | $65 → $82 |
| 31 July 2026 | Mizuho | Maintains | Outperform | — |
| 31 July 2026 | Mizuho | Maintains | Outperform | $90 → $95 |
| 31 July 2026 | Piper Sandler | Reiterates | Overweight | $88 → $95 |
| 31 July 2026 | Piper Sandler | Reiterates | Overweight | — |
| 31 July 2026 | RBC Capital | Maintains | Outperform | — |
| 31 July 2026 | RBC Capital | Maintains | Outperform | $85 → $90 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DXCM appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Sept 2026, DexCom, Inc. returned +29.6% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 19% of US stocks
Cheaper than 7% of US stocks
Cheaper than 12% of US stocks
Higher than 59% of US stocks
Higher than 70% of US stocks
Higher than 77% of US stocks
Higher than 83% of US stocks
Higher than 82% of US stocks
Higher than 91% of US stocks
Higher than 92% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
DexCom, Inc. has a market value of $33.6B and an enterprise value of $33.1B.
Revenue in the twelve months to 30 June 2026: $5.0B. The latest quarter grew 13.1% year on year.
Net income over the same four quarters: $999.7M, a 20.1% net margin.
Diluted earnings per share, trailing twelve months: $2.53.
Free cash flow in the twelve months to 30 June 2026: $1.4B.
Trailing P/E: 35.5×; forward P/E: 28.7× — the forward figure prices analyst consensus estimates, not reported earnings.
DexCom, Inc. employs 11,000 people — $452K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own DexCom, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Oura Inc. launched its IPO roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of September, as highlighted by its $15.6 billion IPO.
Why it matters — A DXCM watcher would care because this IPO draws investor attention to the consumer health-monitoring and wearable technology sector, the wider market space in which DexCom operates.
Dexcom announced the promotion of Jereme Sylvain to Chief Operating Officer. The announcement was made via a press release from San Diego, as reported by Business Wire.
Why it matters — A change in senior leadership, such as a new COO, can signal shifts in operational strategy and management direction that investors following Dexcom would monitor.
Zacks published an article recommending that DexCom stock be retained in portfolios. It highlights DexCom's strong growth, adoption of the G7 15-day sensor, and the CONNECT trial as potential drivers for expanding its continuous glucose monitoring market opportunity, while acknowledging reimbursement and competition risks.
Why it matters — DexCom watchers would care because the piece points to factors that could broaden DexCom's CGM market reach, balanced against reimbursement and competitive pressures facing the company.
DexCom, Inc. announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Boehnlein is a healthcare executive and finance leader with over 20 years of experience in the medical technology industry, most recently serving as Vice President and Chief Financial Officer of Stryker Corporation.
Why it matters — A DXCM watcher would care because adding an experienced med-tech CFO to the board brings senior financial and healthcare leadership expertise to the company's governance.
DexCom, Inc. presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of the session published by Seeking Alpha. The presentation provides an account of the company's remarks at the conference.
Why it matters — DXCM watchers can gain insight into the company's stated positioning and messaging from its official conference remarks.
The 28 Wall Street analysts covering DexCom, Inc. have a median 12-month price target of $94, with estimates ranging from $79 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering DexCom, Inc., 25 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DexCom, Inc. 99 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 23 Sept 2026, DexCom, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (99 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +7.5% from the last close, and Ticker Nerd's factor model ranks DexCom, Inc. 99 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering DexCom, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DXCM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $79 to $115 over the next 12 months.
DexCom, Inc. returned +29.6% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health.
The most recent item we track (MarketBeat, 22 Sept 2026): "Oura's $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring". Oura Inc. launched its IPO roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of September, as highlighted by its $15.6 billion IPO.
DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health. Dexcom develops wearable biosensors, transmitters, receivers, and software that provide real-time glucose readings, trend data, and alerts to help users and clinicians monitor glucose levels without routine fingerstick testing. Its current product lineup includes Dexcom G7, Dexcom G7 15 Day, Dexcom G6, Dexcom ONE+, Stelo, Dexcom Share, and Dexcom Follow, along with digital tools and remote monitoring features that support daily diabetes management. The company serves people with diabetes, adults with prediabetes and type 2 diabetes who do not use insulin, and healthcare professionals across the United States and international markets. Headquartered in San Diego, California, DexCom plays a significant role in the diabetes care technology market through its focus on connected glucose sensing and data-sharing solutions.
CEO Mr. Jacob Steven Leach · 11,000 employees · United States · https://www.dexcom.com
